CytomX Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CytomX Therapeutics, Inc. (CTMX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.58M, a 80.08% increase year-over-year.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.71M, a 134.36% increase year-over-year.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.38M, a 30.63% decline year-over-year.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.43M, a 23.96% decline year-over-year.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.30M, a 17.81% decline from fiscal 2024.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.67M, a 10.40% decline from fiscal 2023.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $8.56M, a 34.80% decline from fiscal 2022.
- CytomX Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $13.13M, a 0.32% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.58M 10-Q · filed 2026-08-06 | $7.28M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $4.71M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $6.30M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $1.38M 10-Q · filed 2025-11-06 | $2.81M derived: sum of 2 quarters · filed 2026-08-06 | $4.82M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.43M 10-Q · filed 2026-08-06 | $3.44M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.01M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $7.67M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-06 | $3.88M derived: sum of 2 quarters · filed 2025-11-06 | $5.78M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.88M 10-Q · filed 2025-11-06 | $3.79M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $1.91M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $8.56M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $1.23M 10-Q · filed 2024-11-07 | $3.60M derived: sum of 2 quarters · filed 2024-11-07 | $6.01M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.37M 10-Q · filed 2024-11-07 | $4.78M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.41M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $13.13M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $2.69M 10-Q · filed 2023-11-07 | $7.18M derived: sum of 2 quarters · filed 2023-11-07 | $10.55M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $4.49M 10-Q · filed 2023-11-07 | $7.86M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $3.37M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $13.17M 10-K/A · filed 2023-03-27 | |||
| 2021-09-30 | $3.16M 10-Q · filed 2022-11-08 | $6.59M derived: sum of 2 quarters · filed 2022-11-08 | $9.62M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.42M 10-Q · filed 2022-11-08 | $6.46M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $3.03M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $14.79M 10-K/A · filed 2023-03-27 | |||
| 2020-09-30 | $3.84M 10-Q · filed 2021-11-04 | $7.35M derived: sum of 2 quarters · filed 2021-11-04 | $11.37M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $3.51M 10-Q · filed 2021-11-04 | $7.53M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $4.01M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $19.10M 10-K/A · filed 2023-03-27 | |||
| 2019-09-30 | $4.34M 10-Q · filed 2020-11-05 | $9.80M derived: sum of 2 quarters · filed 2020-11-05 | $14.99M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $5.45M 10-Q · filed 2020-11-05 | $10.65M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $5.19M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $16.88M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $4.41M 10-Q · filed 2019-11-07 | $8.57M derived: sum of 2 quarters · filed 2019-11-07 | $12.26M derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-06-30 | $4.16M 10-Q · filed 2019-11-07 | $7.85M derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2018-03-31 | $3.69M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $11.29M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $10.10M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $3.99M 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $553.00K 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $343.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |